Tatyana Sharova
Overview
Explore the profile of Tatyana Sharova including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
1107
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Lester D, Burton C, Gardner A, Innamarato P, Kodumudi K, Liu Q, et al.
Nat Cancer
. 2023 Jan;
4(2):222-239.
PMID: 36690875
Immunotherapy efficacy is limited in melanoma, and combinations of immunotherapies with other modalities have yielded limited improvements but also adverse events requiring cessation of treatment. In addition to ineffective patient...
12.
Sun Y, Revach O, Anderson S, Kessler E, Wolfe C, Jenney A, et al.
Nature
. 2023 Jan;
615(7950):158-167.
PMID: 36634707
Despite the success of PD-1 blockade in melanoma and other cancers, effective treatment strategies to overcome resistance to cancer immunotherapy are lacking. Here we identify the innate immune kinase TANK-binding...
13.
Bai X, Shoushtari A, Betof Warner A, Si L, Tang B, Cui C, et al.
Br J Dermatol
. 2022 Mar;
187(3):401-410.
PMID: 35293617
Background: Programmed cell death receptor-1 (PD-1) monotherapy is a standard treatment for advanced cutaneous melanoma, but its efficacy and toxicity are defined in white populations and remain poorly characterized in...
14.
Freeman S, Sade-Feldman M, Kim J, Stewart C, Gonye A, Ravi A, et al.
Cell Rep Med
. 2022 Mar;
3(2):100500.
PMID: 35243413
Immune checkpoint blockade (CPB) improves melanoma outcomes, but many patients still do not respond. Tumor mutational burden (TMB) and tumor-infiltrating T cells are associated with response, and integrative models improve...
15.
Pelka K, Hofree M, Chen J, Sarkizova S, Pirl J, Jorgji V, et al.
Cell
. 2021 Aug;
184(18):4734-4752.e20.
PMID: 34450029
Immune responses to cancer are highly variable, with mismatch repair-deficient (MMRd) tumors exhibiting more anti-tumor immunity than mismatch repair-proficient (MMRp) tumors. To understand the rules governing these varied responses, we...
16.
Bai X, Hu J, Betof Warner A, Quach H, Cann C, Zhang M, et al.
Clin Cancer Res
. 2021 Aug;
27(21):5993-6000.
PMID: 34376536
Purpose: Programmed cell death receptor-1 (PD-1) inhibitors are frontline therapy in advanced melanoma. Severe immune-related adverse effects (irAEs) often require immunosuppressive treatment with glucocorticoids (GCCs), but GCC use and its...
17.
Lenehan P, Cirella A, Uchida A, Crowley S, Sharova T, Boland G, et al.
Immunother Adv
. 2021 Jul;
1(1):ltab011.
PMID: 34291232
Objectives: Cachexia is a systemic metabolic disorder characterized by loss of fat and muscle mass, which disproportionately impacts patients with gastrointestinal malignancies such as pancreatic cancer. While the immunologic shifts...
18.
Liu D, Lin J, Robitschek E, Kasumova G, Heyde A, Shi A, et al.
Nat Med
. 2021 May;
27(6):985-992.
PMID: 33941922
Despite initial responses, most melanoma patients develop resistance to immune checkpoint blockade (ICB). To understand the evolution of resistance, we studied 37 tumor samples over 9 years from a patient...
19.
Bai X, Kim M, Kasumova G, Si L, Tang B, Cui C, et al.
J Immunother Cancer
. 2021 Feb;
9(2).
PMID: 33632901
Background: Although the Society for Immunotherapy of Cancer (SITC) Immunotherapy Resistance Taskforce recently defined primary and secondary resistance to anti-programmed cell death protein 1 (anti-PD-1) therapy, there is lack of...
20.
Saqlain F, Shalhout S, Emerick K, Neilan T, Sharova T, Miller D
Case Rep Dermatol Med
. 2020 Oct;
2020:8890845.
PMID: 33062347
Merkel cell carcinoma is a rare cutaneous neuroendocrine carcinoma with a high rate of regional and distant metastasis and mortality. Here, we report a novel case of Merkel cell carcinoma...